Intellia’s stock rallied after the company reported additional positive secondary endpoint data for lonvoguran ziclumeran (lonvo-z) in the pivotal Phase 3 HAELO trial for hereditary angioedema. The company reported reductions in attack rates requiring on-demand treatment and decreases in moderate-to-severe attack rates over weeks 5–28. Intellia also said the therapy improved patient quality-of-life measures at week 28, with results published in The New England Journal of Medicine and presented at the European Academy of Allergy & Clinical Immunology congress in Istanbul. The company said the data supports its ongoing rolling BLA submission started in April. Management indicated it expects to complete the BLA filing by year-end and target a potential FDA approval and launch in the first half of 2027, increasing scrutiny on final review expectations for gene-editing safety and durable efficacy.